@ninaageezy's GHK-Cu peptide claims need context

What did @ninaageezy actually say?

She ran a six-week cycle of Klow80, a peptide blend that appears to include GHK-Cu, KPV, BPC-157, and TB-500. Her verdict: she liked it, but she's stripping it down. She wants to drop BPC-157 and TB-500 because "I don't have any major injuries," keep KPV because it helped with gut issues and inflammation, and continue GHK-Cu solo for skin, hair, and lash growth. She also reported zero new breakouts during the cycle, significant skin tightening, eyebrow and lash regrowth within two weeks, and ongoing facial dryness she's managing with zinc and moisturizer.

Her reasoning for the protocol change is actually more coherent than most peptide content on TikTok. She's not chasing a stack for its own sake. She's trying to isolate what worked. That said, there are several specific claims here worth scrutinizing.

Does the science back this up?

GHK-Cu has the strongest evidence base of anything she mentioned, and it's still mostly preclinical. KPV has emerging but limited human data. The lash regrowth story is the most eyebrow-raising claim, and the acne clearance attribution is shaky.

GHK-Cu (copper tripeptide-1) does have documented effects on skin remodeling. Pickart and Margolina (2018, Symmetry) reviewed decades of research showing GHK-Cu stimulates collagen and elastin synthesis, activates wound-healing genes, and has anti-inflammatory properties in tissue culture and animal models. Skin tightening and pore appearance improvements are biologically plausible. However, most of this work is in vitro or in small topical studies, not randomized controlled trials of injected GHK-Cu.

KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone. Kannengiesser et al. (2008, Peptides) showed KPV reduced inflammation in murine colitis models. There is very limited human data, and no published clinical trials support using injected KPV for gut health in the way she describes. Her subjective "lighter and more balanced" feeling is not verifiable.

On lash regrowth: GHK-Cu has no published evidence for lash regrowth specifically. Bimatoprost (a prostaglandin analog) has FDA-cleared evidence for this. Attributing her lash growth to GHK-Cu is a reasonable hypothesis, but it is not supported by controlled data.

What did they get wrong (or right)?

She got her reasoning right and her attribution wrong. Stopping BPC-157 and TB-500 because she lacks the injury context they're typically used for is actually a responsible, rational call. Most people running these peptides are doing so without any clinical indication. Credit where it's due.

Where she goes wrong is in confidently attributing specific outcomes to specific peptides in a multi-compound stack. She ran GHK-Cu, KPV, BPC-157, and TB-500 simultaneously for six weeks with no control period. When she says GHK-Cu caused her lash growth or that KPV resolved her gut issues, she has no way to isolate that. BPC-157, for instance, has its own anti-inflammatory and gut-related mechanisms (Sikiric et al., 2016, Current Pharmaceutical Design). It could have contributed to the gut improvements she's attributing entirely to KPV.

The acne claim deserves scrutiny too. "I had no new breakouts" during six weeks is notable for someone who is hormonally acne-prone, but six weeks is within a normal hormonal fluctuation window. Without tracking her cycle timing, stress levels, and diet, this is anecdote, not evidence.

The dryness she reports and her zinc supplementation response is interesting. Zinc has legitimate evidence in acne management (Yee et al., 2020, Dermatologic Therapy) and wound healing. But pairing zinc with a skin-drying protocol without medical supervision is not without risk.

What should you actually know?

Peptide blends like Klow80 are not FDA-approved products. They are typically compounded or research-grade substances, and the evidence supporting their combined use in healthy, non-injured individuals is thin at best. Her instinct to simplify her stack is sound clinical thinking, even if she arrived at it through trial and error rather than a clinician's guidance.

GHK-Cu has a genuinely interesting research profile for skin aging, but the jump from "promising preclinical data" to "my pores are smaller and my lashes grew back in two weeks" is a large one. The two-week lash regrowth timeline in particular should prompt skepticism. Hair and lash follicle cycling does not typically produce visible regrowth in 14 days under any known intervention.

If you are considering peptides for skin or anti-aging purposes, the honest answer is that topical GHK-Cu has more controlled evidence than injected GHK-Cu for cosmetic outcomes. Anyone pursuing injectable peptide protocols should do so through a licensed provider who can assess appropriateness, monitor for adverse effects, and track outcomes with more rigor than a six-week subjective experiment.